ZEAL Stock Overview
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
Zealand Pharma A/S Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.167.00|
|52 Week High||kr.213.00|
|52 Week Low||kr.69.55|
|1 Month Change||31.19%|
|3 Month Change||66.00%|
|1 Year Change||-8.64%|
|3 Year Change||5.23%|
|5 Year Change||38.02%|
|Change since IPO||110.06%|
Recent News & Updates
|ZEAL||DK Biotechs||DK Market|
Return vs Industry: ZEAL matched the Danish Biotechs industry which returned -8.9% over the past year.
Return vs Market: ZEAL matched the Danish Market which returned -9.5% over the past year.
|ZEAL Average Weekly Movement||11.9%|
|Biotechs Industry Average Movement||8.0%|
|Market Average Movement||5.5%|
|10% most volatile stocks in DK Market||10.5%|
|10% least volatile stocks in DK Market||3.0%|
Stable Share Price: ZEAL is more volatile than 90% of Danish stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ZEAL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.
Zealand Pharma A/S Fundamentals Summary
|ZEAL fundamental statistics|
Is ZEAL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ZEAL income statement (TTM)|
|Cost of Revenue||kr.112.39m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
|Earnings per share (EPS)||-23.60|
|Net Profit Margin||-371.73%|
How did ZEAL perform over the long term?See historical performance and comparison